Xtrackers MSCI USA Financials UCITS ETF 1D CHF is a equity ETF from Xtrackers tracking the MSCI USA Financials index through physical replication. Domiciled in Ireland and launched in 2017, the fund manages about 678 M € and charges a TER of 0.12% — 12 € per year on a €10,000 investment. Income is paid out to investors periodically (distributing).
Xtrackers MSCI USA Financials UCITS ETF 1D CHF competes with 359 other products in the same class and region (Equity, USA): it ranks 139th by fund size and 85th by ongoing cost, with a TER of 0.12% against a group median of 0.20%. It has been listed since 2017, 9 years of track record.
On a €10,000 investment the TER costs 12 € a year, against 20 € for the median product in the category.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 54.4% of the portfolio.
Income is distributed periodically: it produces cash flow, but reinvesting it is up to you if the goal is capital growth. The fund is denominated in CHF. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
Irish domicile lets the fund apply the Ireland–US tax treaty, with 15% withholding instead of 30% on US dividends received by the fund.
| JPMorgan Chase & Co | 11.1% |
| Berkshire Hathaway Inc | 8.9% |
| Visa Inc. Class A | 7.5% |
| Mastercard Inc | 5.7% |
| Bank of America Corp | 4.8% |
| Goldman Sachs Group Inc | 4.2% |
| Morgan Stanley | 3.4% |
| Wells Fargo & Company | 3.3% |
| Citigroup Inc. | 3.1% |
| American Express Company | 2.4% |
| XETRA | XUFN | EUR |
| Francoforte | XUFN | EUR |
| London Stock Exchange | XSFN | GBX |
| London Stock Exchange | XUFN | USD |
| SIX Swiss Exchange | XUFN | USD |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.